Rick Simpson Oil (RSO) in Texas: The Complete Guide by OilWell Cannabis

When a paralyzed dog named Bentley stood up, walked across the room, and dropped his ball at Colin’s feet, it wasn’t just a miracle. It was the beginning of a mission that would eventually bring clinical-strength, multi-cannabinoid Rick Simpson Oil to Texans across the state and around the world. That moment in Houston — when conventional veterinary medicine had nothing left to offer and cannabis did what pharmaceuticals couldn’t — is where OilWell Cannabis began. It’s also where our commitment to honest education, open-source transparency, and evidence-based formulations was born.

We built OilWell to be different. Not different in the way that sounds good in marketing copy, but different in the ways that actually matter: we publish exactly what’s in every product, we test everything third-party, we offer same-day delivery in Houston, and we believe so strongly in accessibility that we give away our formulas so people who can’t afford our products can make their own. That’s the Rick Simpson ethos, evolved for a legal, tested, standardized world.

This guide is everything you need to know about Rick Simpson Oil, modern formulated RSO, and how OilWell’s approach fits into the Texas cannabis landscape. We’ve organized it so you can read straight through or jump to the sections most relevant to your situation. Whether you’re a cancer patient exploring options, a veteran managing PTSD, someone struggling with chronic pain, or simply curious about what RSO actually is, you’ll find honest information here — including what the science supports, what it doesn’t, and where the gaps in the evidence still exist.

Understanding Rick Simpson and the Origins of RSO

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, a scientist, or a medical researcher. He was a power engineer and maintenance worker — a tradesman whose path into cannabis advocacy began with personal suffering and a profound distrust of a medical system that couldn’t help him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine failed to resolve. The medications prescribed either didn’t help or made things worse. When he asked his physician about cannabis as an alternative, the request was refused.

This pattern — of the medical establishment failing patients and then dismissing the alternatives those patients sought — would define Simpson’s relationship with conventional medicine for the rest of his life. It also resonates deeply with countless Texans who have experienced the same frustration: being told there’s nothing more that can be done, being cycled through prescriptions that don’t work, and being dismissed when asking about options their doctors won’t discuss.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institutes of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. Originally intended to demonstrate cannabis harm, this study became a foundational reference in Simpson’s advocacy — even though its findings were never replicated in controlled human cancer trials. That distinction matters: the gap between what happens in a petri dish or a mouse and what happens in a human being is vast, and it’s a gap that Simpson’s later claims would repeatedly bridge too quickly.

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome was ever published, no biopsy confirmation exists, and no clinical follow-up was documented in any peer-reviewed source.

Important context: Simpson’s account is presented here as personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement around concentrated cannabis oil — and understanding that distinction is fundamental to evaluating everything that follows.

The Crusade: Spreading the Oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating from his property in Maccan, Nova Scotia, he made oil in large quantities and gave it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and numerous other conditions.

In Texas, this resonates for obvious reasons. Our state has among the highest rates of chronic pain in the country. We have large populations of veterans dealing with PTSD, chronic pain, and the aftermath of traumatic brain injuries similar to Simpson’s. We have cancer patients who have exhausted conventional options and are searching for anything that might help. And we have a healthcare system that, for many Texans, feels inadequate to the scale of suffering it attempts to address. Simpson’s story speaks to all of that.

Simpson’s message reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. For many people — including Texans who discovered it through online forums, cancer patient communities, and word of mouth — Run From The Cure was their introduction to concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005, seizing plants and equipment. He was charged with cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada for Europe, living in Croatia and later the Netherlands.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He maintained phoenixtears.ca as his primary online platform.

Throughout his public career, Simpson’s position remained consistent: he maintained that cannabis oil could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption.

Important context: Simpson’s conspiratorial framing reflects a worldview shared by many in the early cannabis movement. It’s relevant to understanding why RSO became culturally significant, particularly in communities — including many in Texas — that have experienced institutional failure firsthand. The evidence-based assessment of his specific medical claims follows below.

Simpson’s Protocol: The 60-Gram, 90-Day Regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he recommended it for numerous other conditions as well. Understanding this protocol is essential for anyone researching RSO, because you’ll encounter it everywhere in online forums, social media groups, and cancer patient communities. Here’s what Simpson actually recommended.

The Goal: Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum necessary for a serious cancer treatment course.

The Titration Schedule:

• Week 1: Begin with a dose approximately the size of half a grain of dry rice — roughly 10 to 15 milligrams of oil — taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. The initial doses must be very small to allow the body to adjust to THC’s psychoactive effects.

• Weeks 2 through 5: Double the dose approximately every four days. The slow ramp-up builds THC tolerance gradually. By the end of this escalation period — roughly four to five weeks — the target was approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, continuing until the full 60 grams have been consumed.

Administration Methods:

• Primary — oral: Placing the dose directly under the tongue (sublingual) or swallowing it. Simpson considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers.
• Secondary — topical: For skin cancers and external lesions, applying oil directly to the affected area, covering with a bandage, and changing every three to four days. He combined topical with oral dosing for skin cancers.
• Not recommended as primary — inhalation: Simpson acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for sustained, high-dose exposure he considered therapeutically essential.

Tolerance and Psychoactive Effects: Simpson maintained that patients would develop significant tolerance to psychoactive effects within approximately three to four weeks of consistent dosing. He considered the high a minor and temporary side effect and urged patients not to let it discourage them. He recommended taking initial doses at night or before bed to sleep through the most intense effects. He also warned against driving or operating machinery during titration and advised informing family members about what to expect.

Post-Protocol Maintenance: After completing the full 60-gram course, Simpson recommended ongoing maintenance of approximately 1 to 2 grams per month indefinitely.

Dietary Recommendations: Simpson advocated reducing sugar intake, avoiding processed foods, and improving overall nutrition — though his dietary advice was general rather than systematic.

Critical Context for Evaluating This Protocol: This protocol was designed by one person based on personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or formal research. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely depending on starting material and extraction technique.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil daily. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day — a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are documented in peer-reviewed literature and discussed in detail in the science section of this guide.
• Oncology context matters. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment — potentially in place of proven therapies — introduces harm that extends beyond the oil itself.

What Traditional RSO Actually Was

Traditional RSO refers to the specific type of concentrated cannabis oil Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. Understanding what it actually was matters because the term “RSO” is now used loosely across the legal cannabis industry, often bearing little resemblance to Simpson’s original product.

Source Material: Simpson used high-THC, indica-dominant cannabis strains, specifically favoring heavy, sedating indica genetics. He grew his own or sourced from trusted growers. There was no strain standardization — the starting material varied by availability and growing season.

Extraction Solvent: Simpson originally used naphtha — a petroleum-based solvent commercially available as lighter fluid or similar products. He later endorsed 99 percent isopropyl alcohol as an alternative. Neither is a food-grade solvent, which is a significant safety issue. He explicitly warned against butane or acetone.

Extraction Process: Dry or semi-dry cannabis plant material was placed in a container, covered with solvent, and agitated to dissolve cannabinoids. The solvent was poured off through cheesecloth or mesh into a collection vessel. The process repeated with fresh solvent on the same material. The combined solvent washes — now a dark, cannabinoid-rich liquid — were placed in a rice cooker or similar open-vessel heating device. The solvent evaporated at relatively low heat (rice cookers maintain temperatures that evaporate solvents without exceeding cannabinoid degradation thresholds). However, this heat was still high enough to decarboxylate THCa into THC and destroy most volatile terpenes. The final oil was transferred into oral syringes for storage and dosing.

Appearance: Traditional RSO was nearly black, thick, and tar-like. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on purging thoroughness.

Cannabinoid Profile: Primarily decarboxylated delta-9 THC. The heat converted essentially all THCa into delta-9 THC. Minor cannabinoids existed at natural ratios from the source strain but were not controlled, measured, or targeted. Traditional RSO likely ranged from 60 to 90 percent THC by weight, though this was never lab-verified in Simpson’s production context.

Terpene Content: Minimal to none. The combination of solvent extraction and high-heat evaporation destroyed terpenes almost entirely.

Standardization and Testing: None. Every batch was different depending on starting material, growing conditions, solvent purity, extraction technique, and evaporation parameters. Simpson operated before legalization and standardized lab-testing infrastructure. There was no Certificate of Analysis, no cannabinoid quantification, no contaminant screening.

Residual Solvent Risk: This is one of the most significant safety concerns. Naphtha is a complex petroleum hydrocarbon mixture potentially containing benzene, toluene, and other toxic or carcinogenic compounds. Incomplete purging — difficult to verify without lab testing — left potentially harmful residues in finished oil.

What Simpson Claimed vs. What the Evidence Shows

Rick Simpson made expansive therapeutic claims. He stated that RSO could cure cancer — including terminal cases — and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions.

What Simpson Was Not: Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. His entire evidence base consisted of personal experience and informally gathered testimonials — with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows: The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting. In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines. Animal model studies have shown some tumor-growth inhibition in mice and rats. These findings have generated legitimate scientific interest and ongoing research.

What the Preclinical Literature Does Not Show: These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast and well-documented across all of oncology research. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer. Several small human trials of cannabinoids in cancer contexts have been conducted, but they have been exploratory, small, and have not produced results supporting cancer-cure claims.

Institutional Positions: The National Cancer Institute acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment. The FDA has not approved any cannabis plant product for the treatment of cancer. Health Canada has never approved RSO or cannabis oil as a cancer cure. The National Center for Complementary and Integrative Health (NCCIH) explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS — not cancer cure.

What Simpson Got Right: Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or suppressing that conversation. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and the research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and “RSO” remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary.

What He Overstated: The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients — particularly cancer patients — to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty exceeded what the evidence could support and still exceeds it today.

The Evolution: Traditional RSO vs. Modern Formulated RSO

The term RSO is now used broadly — and often loosely — across the legal cannabis industry. Many products labeled RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself was critical of commercial products using the RSO name while departing significantly from his original method. He publicly stated that many products sold as RSO didn’t meet his standards and that commercialization contradicted his original intent. Simpson’s model was explicitly anti-commercial — he gave oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model. The modern cannabis industry has done something different: commercialized, standardized, and regulated what Simpson distributed for free. Whether that represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and gatekeeping) depends on perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins.

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined profile
Standardization	None — every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge
THCa preservation	No — fully decarboxylated	Yes — THCa at 1,500 mg as separate ingredient
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverged from Traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways.

Multi-Cannabinoid Approach: Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids — CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC — because the entourage-effect literature suggests potential benefit from cannabinoid diversity. This doesn’t mean the whole-formula synergy is proven — it means the science is interesting enough to pursue, and we’re transparent about where the evidence stands.

Terpene Preservation and Addition: Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile — limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene — because terpene bioactivity is plausible and supported at the preclinical level. We’ll be honest: human clinical confirmation for cannabis-specific terpene effects is still developing.

THCa as a Separate Ingredient: Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

Reduced Delta-9 THC Dominance: Traditional RSO was overwhelmingly delta-9 THC — often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

Product Format Innovation: Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol — neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds with established toxicity. Isopropyl alcohol, while cleaner than naphtha, is also not intended for internal consumption. Incomplete solvent purging — very difficult to verify without analytical chemistry equipment — leaves potentially harmful residues.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods. This is one of the most straightforward improvements the modern regulated industry has made over traditional RSO production.

Texas has seen its share of contaminated cannabis products, particularly during the Delta-8 boom of 2020-2021 when companies rushed products to market without adequate testing. We believe solvent-free production and comprehensive third-party testing aren’t optional extras — they’re the minimum standard responsible companies should meet.

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent — sustained at roughly 60 to 80 degrees Celsius for naphtha and approximately 82 degrees Celsius for isopropyl alcohol — was sufficient to convert essentially all THCa into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material — including THCa, CBDa, CBGa, and others — were lost as distinct compounds in traditional RSO.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage.

OilWell’s Origin: From Bentley to Houston

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin’s story is not a polished brand narrative — it’s the actual experience of someone who grew up in one of the most challenging environments in America and chose cannabis over darker paths.

Colin grew up in McAllen, Texas, right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area — the Borderplex — is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts: vibrant culture and thriving retail alongside deep poverty and limited opportunities outside retail and healthcare. Reynosa, across the river, is an industrial hub plagued by violence and cartel activity.

Colin’s childhood was marked by exposure to both the opportunities and dangers of life along the border. He learned to hustle early, taking on risky work. His best friends have been killed or are in prison. He faced every form of violence imaginable, in the streets and across the border. By sixteen, he had to leave home for good.

Despite the dangers, Colin didn’t fall into the darkest paths available to him. He focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine — one of the most prestigious institutions in the Texas Medical Center. That combination — deep cannabis plant knowledge plus medical-grade technical precision — would define OilWell’s approach.

Bentley: The Dog Who Changed Everything

The company’s origin story begins with a dog named Bentley. Bentley was more than a pet — he was family. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley wasn’t an option. Colin had already faced too much loss and seen too much suffering. Bentley was a fighter, and Colin wasn’t ready to let him go.

In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything. A kind-hearted rescue worker named Jessica asked him: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience — but it was recreational. Getting high. He had never explored therapeutic applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste — a specialized cannabinoid formula for pets. It wasn’t a cure, but it was a lifeline and hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play.

From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect — dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals couldn’t.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced:

• Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection.
• Dementia led him to CBC’s role in neurogenesis.
• Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction.
• Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone couldn’t address neurodegeneration and dementia and glaucoma and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered — Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that alleviate pain and suffering, not just for pets but for people. Bentley’s story is the foundation of OilWell Cannabis, driving commitment to quality, innovation, and compassionate care.

Colin’s Personal Journey: PTSD, Benzodiazepines, and Peace Gummies

Colin knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey — a feat notoriously difficult and dangerous — using the cannabinoid knowledge he had developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in vape form, which Colin personally uses to manage his insomnia and severe PTSD on an ongoing basis.

This isn’t theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills don’t.

Over time, the therapeutic benefits Colin first discovered through saving Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

OilWell’s Philosophy: Four Core Principles

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Simpson’s original vision.

Accessibility Over Gatekeeping: No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally.

Patient-Controlled Potency: THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry.

Open-Source Formulas: OilWell publishes complete formulas publicly — every cannabinoid, every milligram amount, every percentage — so that anyone who cannot afford the products can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos by selling a professionally manufactured product and publishing the recipe.

Evidence-Informed, Not Evidence-Overstating: The science section of this guide represents OilWell’s commitment to honest education about what the research actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

As Colin said on ABC13 Houston in September 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Farm Bill Compliance and the THCa Legal Framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle — 3 milligrams per milliliter — well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

THCa — tetrahydrocannabinolic acid — is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it hasn’t been converted to delta-9 THC.

The practical significance is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams already in the formula, this produces approximately 1,405 milligrams of total delta-9 THC — giving the product psychoactive potency comparable to traditional high-THC RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. This enables international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Why OilWell Publishes Everything

OilWell publishes their complete RSO formulas — every cannabinoid, every milligram, every percentage — in public documents including this guide. The rationale is straightforward: if someone cannot afford OilWell’s products, they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern marketplace: selling a professionally manufactured, lab-tested, standardized product for those who want it, and publishing the complete recipe for those who want to make it themselves.

The open-source philosophy didn’t start with RSO — it started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis could make it themselves:

CBD Golden Paste Recipe for Pets:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size and needs; consult with a veterinarian)

Instructions:

1. Mix turmeric and water in a saucepan over low heat, stirring continuously until it forms a thick paste (7 to 10 minutes). Add more water if too thick.
2. Add coconut oil and black pepper. Stir until thoroughly mixed.
3. Cool and store in a jar with a lid in the refrigerator for up to two weeks.
4. Add CBD oil to the paste before giving it to your pet, adjusting based on weight and health needs. Start low and increase gradually.

This recipe — published for free, years before the RSO formulas were open-sourced — demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos isn’t a marketing strategy. It’s the foundational behavior of the company.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1 — Raw, No Heat: All 1,500 milligrams stays as THCa — completely non-psychoactive. THCa evidence suggests anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2 — Fully Activated, Home Decarboxylation: Heating at 260°F for 45 to 60 minutes converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO — 100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase. Customers may also decarboxylate only a portion and preserve the remainder in raw THCa form.

Option 3 — Vape, Auto-Decarboxylation: The RSO Vape Cartridge vaporizes at 400 to 450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands.

Solvent-Free Production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile — a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The Broader Product Portfolio

Beyond RSO, OilWell produces a range of cannabinoid products developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

The Asshole Peach — OilWell’s most popular product. A carefully formulated experience designed to provide a euphoric, long-lasting sensation. Particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. At 268mg total cannabinoids per ring (28mg Delta-9 THC, 50mg Delta-8 THC, 20mg Delta-10 THC, 20mg THCo, 100mg CBD, 50mg CBG), these are serious products for serious needs.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in vape form for quick relief — Colin personally uses the vape to manage his insomnia and severe PTSD. With 320mg total cannabinoids per peach (30mg CBN, 15mg Delta-9 THC, 25mg Delta-8 THC, 100mg CBD, 150mg CBG), this is medicine designed by someone who needed it to work.

SWEETEMintz Sugar-Free Vegan Peppermint Hard Candy — For health-conscious consumers and diabetics. 28mg Delta-9 Nano THC, 100mg Nano CBD, 50mg CBG Isolate. Zero sugar, 100% vegan.

Custom Creations — OilWell designs tailored products on request for specific cannabinoid ratios, delivery formats, or health circumstances including formulations for vegans, diabetics, and those with specific dietary needs.

Two Product Formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent
• Automatic THCa decarboxylation at vaping temperature

When to Use Each Format:

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Delivery and Global Accessibility

OilWell operates the only same-day RSO delivery system in Houston. Beyond Houston, the company ships nationwide and internationally.

Houston Same-Day Delivery:

Zone	Coverage	Delivery Fee
Texas Medical Center	All 60+ TMC institutions	FREE
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5
Within Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Hobby Airport area	$10
Greater Houston suburbs	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15
Extended region (60 miles)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20-$25

Free delivery to the Texas Medical Center — the world’s largest medical complex with over 10 million patient visits annually — reflects OilWell’s commitment to accessibility for patients who need it most. MD Anderson Cancer Center, Memorial Hermann, Houston Methodist, Texas Children’s Hospital, St. Luke’s, and more than 60 other institutions are all in our free delivery zone.

Nationwide Shipping: All 50 states where Farm Bill-compliant products are legal. USPS Priority Mail (2-3 business days), FedEx and UPS Ground (3-5 business days). Discreet packaging, tracking provided, temperature-stable packaging for summer shipments.

International Shipping: OilWell ships internationally and has delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

All international packages include full documentation, COAs, and receipts for customs purposes. Customers verify legality in their jurisdiction and accept all customs and legal risk.

Contact: (832) 416-2816 or [email protected]

The significance of international access cannot be overstated. Rick Simpson could not ship his oil anywhere — it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Germany, a chronic pain patient in Australia, or a veteran in the United Kingdom can now potentially access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery.

The Science: What the Research Actually Says

We believe you deserve honest information about what the science supports, what it doesn’t, and where the gaps remain. This isn’t the most exciting way to present cannabis products, but it’s the right way.

Research Method and Evidence Weighting: We prioritize sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic or preclinical literature when human data are sparse. The evidence base is not evenly distributed. CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

Institutional Baseline from NIH: The National Center for Complementary and Integrative Health states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research.

The FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.

Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns.

The Cannabinoids in OilWell’s Formula

CBD (Cannabidiol): The strongest human evidence in the current formula set, especially when studied as a purified product rather than a loose wellness ingredient. Purified CBD has the most credible human evidence in seizure disorders — this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature. A 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but authors stressed that the clinical sample remains limited and more trials are needed. A 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency limiting confidence in broad analgesic claims. A 2023 insomnia review found that the literature remains methodologically weak. A 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts — especially relevant for concentrated oral products and polypharmacy settings. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions.

Bottom line: CBD is the most evidence-developed non-intoxicating cannabinoid in this guide, but even here, strong evidence is concentrated in a few specific indications rather than in the broad, generalized wellness claims often seen in marketing.

CBG (Cannabigerol): Mostly review-level and preclinical; human evidence remains sparse. CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, making it mechanistically interesting but not yet clinically established. Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions. One key point: CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.

Bottom line: CBG is a promising minor cannabinoid with limited clinical validation rather than a proven therapeutic cannabinoid.

Delta-8 THC: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC. A 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with CB1 affinity weaker than delta-9 THC. A 2023 scoping review found that much of the delta-8 evidence base is dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review noted reports of adverse consequences and emphasized regulatory and product-quality concerns.

Bottom line: Delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa (Tetrahydrocannabinolic Acid): Important chemically and formulation-wise, but still low on direct human therapeutic evidence. THCa is the acidic precursor of THC and may represent a very large share of THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing. The major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated. In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.

Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage.

Delta-9 THC: Strongest human evidence of the psychoactive cannabinoids, but also the clearest adverse-effect burden. NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis and pain-related outcomes. A 2022 systematic review found that products with high THC content may provide short-term pain benefit but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events. A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in non-therapeutic settings. Institutional literature also describes anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns.

Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries the clearest intoxication, psychiatric, and dose-related safety liabilities.

CBN (Cannabinol): Weak human evidence; marketing has clearly moved ahead of the data. CBN is often marketed for sleep and sedation with a widespread reputation, but clinical support is far thinner. The 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN. The 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still doesn’t match the scale of real-world use.

Bottom line: CBN is one of the clearest examples where cultural reputation is stronger than the current clinical evidence base.

CBC (Cannabichromene): Emerging, intriguing, and still overwhelmingly preclinical or review-based. The 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets. Older review literature reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims. The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.

Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives.

The Terpenes: What the Science Suggests

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. Terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene: Largely review and preclinical, with useful safety literature. A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature. Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens.

Myrcene: Mostly preclinical, with very limited human evidence. The 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties, but explicitly states that human studies are lacking. Myrcene is often invoked as a proven sedating terpene that explains couch-lock or sleep effects — that is a stronger claim than the human evidence currently supports.

Caryophyllene: Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical. A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms. Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, and gastroprotective actions are repeatedly discussed, but human clinical confirmation remains limited.

Pinene: Promising preclinical literature, weak human clinical confirmation. The 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but emphasized that evidence is mostly preclinical and well-designed clinical trials are lacking. Claims that pinene reliably improves memory or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.

Linalool: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation. Repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation while emphasizing the lack of robust human trials. As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.

Humulene: Translationally interesting, but still early. A 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways. Those findings are valuable for hypothesis generation but do not yet establish consistent human efficacy.

Terpinolene: One of the least clinically characterized terpenes in this guide. The 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials.

Common Overstatements to Avoid

Overstatement: CBN is a clinically proven sleep cannabinoid.
More accurate: The specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.

Overstatement: Myrcene is a proven human sedative that reliably explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.

Overstatement: Terpenes in general have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

Overstatement: THCa is always non-psychoactive.
More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure.

Overstatement: Delta-8 THC is safe because it is hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Condition-Specific Usage Context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited throughout this guide and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support:

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy):

• Daytime: 0.3 to 0.5 mL raw sublingual — provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual — combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Sleep Support:

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN
• At 1.0 mL, this delivers 25 mg CBN — above the threshold associated with reduced sleep disturbance in published research

Anxiety and Stress:

• Daytime functional relief: 0.3 mL raw sublingual — CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual — full cannabinoid profile including CBN for sleep architecture

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Why Simpson’s Protocol Differs from Modern Dosing

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison between Simpson’s recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward — the products are fundamentally different.

Cannabinoid concentration: OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.

Cannabinoid ratios: Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg) — a completely different pharmacologic profile.

Delta-9 THC exposure: Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence profiles and responsible titration principles that account for each individual cannabinoid’s safety profile.

Media Recognition: What Independent Reporting Says

Between September 2019 and April 2023, ABC13 Houston (KTRK) — the ABC affiliate serving the fourth-largest city in the United States — featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period.

The features document a consistent pattern. When ABC13 needed to explain a new cannabis product to its audience, it called Colin. When a state agency reversed course on Delta-8 legality overnight, it called Colin. When a sitting president announced marijuana pardons and the station needed someone who had personally lived with a cannabis conviction to put it in context, it called Colin. When the station wanted to tell the story of a growing industry on 4/20, it was Colin’s hemp field and Colin’s voice that anchored the report.

In September 2019, Colin told ABC13: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

In May 2021, Colin appeared on ABC13’s investigative segment about Delta-8 THC. When asked why someone would want to smoke Delta-8, he answered: “I don’t give a s*** if it’s wrong to say you’ll get high off it. Maybe you want to get high.” That exchange — radical honesty on mainstream television — became one of Colin’s most iconic media moments.

In October 2021, when Texas DSHS suddenly classified Delta-8 as Schedule I overnight, ABC13 returned to OilWell’s dispensary. Colin had already removed all Delta-8 products from his shelves — proactively, before enforcement began — and was trying to spread the word to other operators who were unknowingly shipping what had become Schedule I narcotics.

In October 2022, when President Biden pardoned federal marijuana convictions, ABC13 revealed that Colin himself has a personal marijuana conviction history. “I would love to see people not get hurt for this anymore,” he said.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, most quotable, and most accessible voice in Houston’s legal cannabis industry. That is the kind of recognition that cannot be purchased — it can only be earned.

Operating Today: Houston, Texas

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed.

OilWell’s products are not mass-produced. They are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas.

Business Hours:

• Monday-Thursday: 10:00 AM – 7:00 PM
• Friday-Saturday: 10:00 AM – 10:00 PM
• Sunday: 10:00 AM – 4:00 PM

Contact:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Instagram: @oilwellcbd

Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

Ready to Learn More or Place an Order

This guide has covered the history of Rick Simpson Oil, what modern formulated RSO actually is, the science behind each cannabinoid and terpene in OilWell’s formulas, the evidence for and against specific therapeutic applications, and how OilWell’s approach differs from traditional RSO and from what you’ll find elsewhere.

If you’re ready to explore OilWell’s products, visit oilwellcbd.com. If you have questions, call (832) 416-2816 or email [email protected]. Same-day delivery is available throughout Houston, including free delivery to the Texas Medical Center.

If you can’t afford our products but want to try a multi-cannabinoid RSO formula, this guide includes the complete recipe. Source the individual cannabinoid distillates and isolates, combine them at the specified ratios, and make your own. That’s what the open-source ethos means.

And if you’re researching RSO for yourself or a loved one — whether you’re dealing with cancer, chronic pain, PTSD, insomnia, or any other condition — we encourage you to talk to your healthcare provider. Cannabis medicine can complement conventional care, but it shouldn’t replace it without informed deliberation and honest conversation about what the evidence actually shows.

We believe you deserve the best possible version of the information so you can make your own decision about whether cannabinoids are right for you. That belief drove everything from Bentley’s recovery to this guide you’re reading now.

Bentley got up. He walked across the room. He brought his ball to play. That’s the moment this started. Everything else — the formulas, the testing, the education, the open-source publication — is an attempt to give more people the chance to see something they thought was impossible.

FDA disclosure: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Consult a physician before use, especially if you are pregnant, nursing, taking medications, or have a medical condition. Keep out of reach of children. Do not operate vehicles or machinery while under the influence.

Legal disclosure: All products contain less than 0.3% delta-9 THC by dry weight and are Farm Bill compliant. THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with local laws. Void where prohibited.